Homepage Top Section2

Under the deal terms, the company will provide funding for clinical development of its next-generation antibody-drug conjugate (ADC), NAV-001. The experimental ADC targets and kills tumour cells which

The double-blind, multicentre, placebo-controlled, randomised, dose-finding Phase II OCEAN(a)-DOSE study was designed for evaluating olpasiran’s tolerability, safety, as well as the optimal dose in atherosclerotic cardiovascular disease (ASCVD)

The financial details of the agreement are not disclosed by the companies. Under the deal, CSL will acquire exclusive and global license to TS23, an enhanced first-in-class anti-α2-antiplasmin

The collaboration will use Charles River’s contract development and manufacturing (CDMO) services to manufacture plasmid DNA and viral vectors for late-stage clinical trials that target degenerative ocular diseases,

The new combined formulation will be delivered using a breath-actuated nebuliser. Currently, AeroRx is said to be engaged in the development of the first nebulised LABA/LAMA combination solution

The latest announcement is expected to be beneficial for nearly 1,500 people aged 12 years and above with melanoma. This drug is said to be the first NICE-recommended

A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells/tumours which harbour deficiency in homologous recombination repair (HRR),

Forxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is administered orally once every day. It has shown efficacy in preventing and delaying cardiorenal disease, while protecting the

Ultomiris is a long-acting C5 complement inhibitor that provides immediate, complete and sustained complement inhibition. It is indicated for adult gMG patients, who are anti-acetylcholine receptor (AChR) antibody-positive,